Lars Maegdefessel, MD, PhD

Experimental Vascular Surgery and Vascular Biology Laboratories, Technical University Munich, Klinikum rechts der Isar, Department of Vascular and Endovascular Surgery, Munich Germany;
Molecular Vascular Medicine Unit, Department of Medicine at the Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden

Dr. Maegdefessel has a dual affiliation, and is a Heisenberg Professor in Vascular Biology at the Technical University in Munich, Germany and a Senior Researcher and Group Leader at the Center for Molecular Medicine at the Karolinska Institute and University Hospital in Stockholm, Sweden. In Munich he is a Principal Investigator of a Research Group embedded in the German Center for Cardiovascular Research (DZHK). He further takes part in EU consortia (Taxinomisis, EU Horizon 2020), a Collaborative Research Center (CRC1123) of the German Research Council (DFG) entitled ‘Atherosclerosis - Mechanisms and Networks of Novel Therapeutic Targets’, and Digimed Bavaria, a precision medicine approach that aims at optimizing the treatment of patients with carotid artery disease and ischemic forms of stroke.

Dr.Maegdefessel studied Medicine at the Johannes Gutenberg University in Mainz, Germany.After receiving his doctorate and completing a clinical fellowship in cardiology, he joined the Division of Cardiovascular Medicine at Stanford University, USA. After spending 3 years as a postdoctoral researcher in Stanford, he accepted an appointment as Assistant Professor of Molecular Vascular Medicine at the Karolinska Institute in Stockholm, Sweden. In spring 2016 he was appointed Professor of Vascular Biology at TUM.

Dr. Maegdefessel is interested in the contribution of non-coding RNAs to vascular disease development and progression. Within vascular pathologies, his research team focuses on atherosclerotic plaque vulnerability and expanding aortic aneurysms, utilizing a variety of translational approaches to discover novel treatment and detection methods on a molecular basis.

Candidate non-coding RNAs and their putative gene (mRNA) targets and proteins are profiled and detected through different transcriptomic (RNA sequencing, microarrays),proteomic, epigenomic and genetic analyses applications. Discoveries from human profiling studies are extensively investigated in pre-clinical models of vascular diseases, allowing his team to better understand the physiological and pathological function and dysfunction of non-coding RNA modulation. In vitro studies, including artery-on-a-chip systems and single cell sequencing, are deployed for in-depth mechanistic studies in disease-relevant cell types and conditions.

In 2016, Dr. Maegdefessel was appointed with a Heisenberg Professorship of the German Research Council (DFG), and won the Werner Risau Award in Vascular Biology from the American Heart Association for his translational work on the therapeutic potential of microRNAs in vascular diseases. In 2015, he received an ERC Starting Grant (acronym NORVAS) to study the role and contribution of long non-coding RNAs in aortic aneurysms. He was further appointed a Ragnar Söderberg Fellow in Medicine and received the Prince Daniel Research Prize from the Swedish Heart Lung Foundation (HLF), both in 2014. In 2018 and 2019, he is the vice chair of the Atherosclerosis Thombosis and Vascular Biology Council Vascular Discovery meeting of the American Heart Association. In 2020 and 2021 he will chair the meeting. He has published over 80 original articles, reviews and editorials since 2008, including publications in Nature, Nature Medicine, Nature Communications, Science Translational Medicine, The Journal of Clinical Investigation, Circulation, and Circulation Research among others.

Dr. Maegdefessel is a member of the Munich Heart Alliance, the German Society for Cardiovascular Medicine (DFG), the American Heart Association (AHA), and the European Society of Cardiology (ESC). The lab takes further part in the Cardiolinc network and the RNA Society of Sweden.

Terms of Appointment: Aug 2018 - Jul 2020